Logo image
Back
Mechanism of isoniazid-induced hepatotoxicity: Then and now
Journal article   Peer reviewed

Mechanism of isoniazid-induced hepatotoxicity: Then and now

I. Metushi, J. Uetrecht and E. Phillips
British Journal of Clinical Pharmacology, Vol.81(6), pp.1030-1036
2016
DOI: https://doi.org/10.1111/bcp.12885
url
Free to Read *No subscription requiredView

Abstract

Isoniazid (INH) remains a mainstay for the treatment of tuberculosis despite the fact that it can cause liver failure. Previous mechanistic hypotheses have classified this type of drug-induced liver injury (DILI) as ‘metabolic idiosyncrasy’ which was thought not to involve an immune response and was mainly due to the bioactivation of the acetylhydrazine metabolite. However, more recent studies support an alternative hypothesis, specifically, that INH itself is directly bioactivated to a reactive metabolite, which in some patients leads to an immune response and liver injury. Furthermore, there appear to be two phenotypes of INH-induced liver injury. Most cases involve mild liver injury, which resolves with immune tolerance, while other cases appear to have a more severe phenotype that is associated with the production of anti-drug/anti-CYP P450 antibodies and can progress to liver failure.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

41 Record Views
160 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.117 Pharmacology & Toxicology
1.117.1309 Drug-Induced Hepatotoxicity
Web Of Science research areas
Pharmacology & Pharmacy
ESI research areas
Pharmacology & Toxicology
Logo image